leadf
logo-loader
viewTissue Regenix Group PLC
(
AIM:TRXOTC:TSSNF
)

Tissue Regenix delivers first-half results that show a strong recovery as it builds its portfolio

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) CEO Danny Lee and CFO David Cocke joined Proactive's Stephen Gunnion with details of the company's interim results, which show a strong recovery following the coronavirus (COVID-19) pandemic with revenues up 21% in constant currency.

Lee telling Proactive that Tissue also successfully completed Phase 1 of its facility expansion in the period and successfully completed development of two additional products to its portfolio.

Quick facts: Tissue Regenix Group PLC

Follow
AIM:TRX

Price: 0.61 GBX

Market Cap: £42.9 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Tissue Regenix Group 'has evolved from an R&D organisation to now focus on...

Tissue Regenix Group PLC's (LON:TRX) CEO Danny Lee and CFO David Cocke about their final results for the year which ended 31 December 2020. The firm is now confident in its prospects once the COVID-19 pandemic has subsided and healthcare procedures return to a normalised level. The represent...

on 04/28/2021

2 min read